Intervention Protocol

Bisphosphonates in early prostate cancer

  1. Nick Pavlakis1,*,
  2. Dinesh Patel2,
  3. Martin R Stockler3

Editorial Group: Cochrane Prostatic Diseases and Urologic Cancers Group

Published Online: 16 JUL 2008

DOI: 10.1002/14651858.CD006249

Database Title

Additional Information

How to Cite

Pavlakis N, Patel D, Stockler MR. Bisphosphonates in early prostate cancer (Protocol). Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006249. DOI: 10.1002/14651858.CD006249.

Author Information

  1. 1

    Royal North Shore Hospital, Department of Medical Oncology, St Leonards, NSW, Australia

  2. 2

    Canterbury Hospital, Surgery, Syndney, New South Wales, Australia

  3. 3

    University of Sydney, NHMRC Clinical Trials Centre and Sydney Cancer Centre, Camperdown, NSW, Australia

*Nick Pavlakis, Department of Medical Oncology, Royal North Shore Hospital, Pacific Highway, St Leonards, NSW, 2065, Australia. pavlakis@med.usyd.edu.au.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 16 JUL 2008

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Full (107K)
 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

Our aim is to determine the benefits and harms of bisphosphonate therapy for men with prostate cancer without clinically evident metastases.

Specific primary objective

To determine the effects of bisphosphonates in men with prostate cancer but without clinically evident metastases on:
i) the incidence of skeletal metastases and their associated clinical complications;
ii) bone mineral density and secondary osteoporotic skeletal complications.

Secondary objectives include the effect of bisphosphonates on:

  1. time to first skeletal complication;
  2. skeletal metastasis event rate;
  3. overall survival;
  4. quality of life;
  5. toxicity.

View Full Article (HTML) Full (107K)